Daniel Karl

1.2k total citations
19 papers, 597 citations indexed

About

Daniel Karl is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Daniel Karl has authored 19 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Oncology. Recurrent topics in Daniel Karl's work include Epigenetics and DNA Methylation (4 papers), Sarcoma Diagnosis and Treatment (4 papers) and Cancer-related gene regulation (4 papers). Daniel Karl is often cited by papers focused on Epigenetics and DNA Methylation (4 papers), Sarcoma Diagnosis and Treatment (4 papers) and Cancer-related gene regulation (4 papers). Daniel Karl collaborates with scholars based in United States, Germany and Singapore. Daniel Karl's co-authors include Fan Liu, Na Man, Concepción Martínez, Adnan K. Mookhtiar, Ramiro E. Verdún, Sarah Greenblatt, Stephen D. Nimer, Pierre-Jacques Hamard, Stéphanie Duffort and Sam S. Yoon and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Daniel Karl

18 papers receiving 590 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Karl United States 12 351 135 102 86 76 19 597
Manoj Kandpal United States 11 321 0.9× 93 0.7× 55 0.5× 68 0.8× 55 0.7× 22 715
Sheng Han China 17 355 1.0× 100 0.7× 93 0.9× 92 1.1× 43 0.6× 33 586
Thu Le Trinh United States 11 205 0.6× 95 0.7× 27 0.3× 50 0.6× 61 0.8× 20 425
Ningning Dong China 11 194 0.6× 178 1.3× 93 0.9× 25 0.3× 44 0.6× 20 479
Takao Ide Japan 15 284 0.8× 321 2.4× 187 1.8× 93 1.1× 202 2.7× 57 843
Alessio Fabozzi Italy 13 221 0.6× 264 2.0× 108 1.1× 75 0.9× 52 0.7× 32 507
Dilara Akhoundova Switzerland 12 148 0.4× 247 1.8× 118 1.2× 28 0.3× 17 0.2× 45 425
Ágnes Holczbauer United States 14 353 1.0× 221 1.6× 76 0.7× 69 0.8× 201 2.6× 18 727

Countries citing papers authored by Daniel Karl

Since Specialization
Citations

This map shows the geographic impact of Daniel Karl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Karl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Karl more than expected).

Fields of papers citing papers by Daniel Karl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Karl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Karl. The network helps show where Daniel Karl may publish in the future.

Co-authorship network of co-authors of Daniel Karl

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Karl. A scholar is included among the top collaborators of Daniel Karl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Karl. Daniel Karl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Nuttall, Barrett, Daniel Karl, Kathleen A. Burke, et al.. (2025). Comprehensive comparison of enzymatic and bisulfite DNA methylation analysis in clinically relevant samples. Clinical Epigenetics. 17(1). 156–156.
2.
Criscione, Steven W., Matthew J. Martin, Derek B. Oien, et al.. (2022). The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells. npj Precision Oncology. 6(1). 95–95. 22 indexed citations
3.
Karl, Daniel, et al.. (2022). LOKAL-digital - Smart Knowledge Management for Housing, Care and Health. 1–4. 2 indexed citations
4.
Burke, Kathleen A., Barrett Nuttall, Daniel Karl, et al.. (2021). Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing. Blood. 138(Supplement 1). 4361–4361. 1 indexed citations
5.
Liu, Fan, Ye Xu, Xiaoqing Lu, et al.. (2020). PRMT5-mediated histone arginine methylation antagonizes transcriptional repression by polycomb complex PRC2. Nucleic Acids Research. 48(6). 2956–2968. 45 indexed citations
6.
Zhang, Yusheng, Ho Lam Chan, Liliana Garcia-Martinez, et al.. (2020). Estrogen induces dynamic ERα and RING1B recruitment to control gene and enhancer activities in luminal breast cancer. Science Advances. 6(23). eaaz7249–eaaz7249. 35 indexed citations
7.
Xu, Ye, Na Man, Daniel Karl, et al.. (2019). TAF1 plays a critical role in AML1-ETO driven leukemogenesis. Nature Communications. 10(1). 4925–4925. 34 indexed citations
8.
Man, Na, Glòria Mas Martín, Daniel Karl, et al.. (2019). EP300 Suppresses Leukemia Development in Myelodysplastic Syndrome through Myb Repression. Blood. 134(Supplement_1). 561–561. 1 indexed citations
9.
Hamard, Pierre-Jacques, Fan Liu, Daniel Karl, et al.. (2018). PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes. Cell Reports. 24(10). 2643–2657. 142 indexed citations
10.
Zofka, Marc René, Stefan Ulbrich, Daniel Karl, et al.. (2018). Traffic Participants in the Loop: A Mixed Reality-Based Interaction Testbed for the Verification and Validation of Autonomous Vehicles. 3583–3590. 12 indexed citations
11.
Mookhtiar, Adnan K., Sarah Greenblatt, Na Man, et al.. (2018). CARM1 Inhibition: Evaluation of Response and Efficacy in Acute Myeloid Leukemia. Blood. 132(Supplement 1). 2719–2719. 1 indexed citations
12.
Man, Na, Yurong Tan, Xiao‐Jian Sun, et al.. (2017). Caspase-3 controls AML1-ETO–driven leukemogenesis via autophagy modulation in a ULK1-dependent manner. Blood. 129(20). 2782–2792. 38 indexed citations
13.
Kambadakone, Avinash, Sam S. Yoon, Tae‐Min Kim, et al.. (2014). CT Perfusion as an Imaging Biomarker in Monitoring Response to Neoadjuvant Bevacizumab and Radiation in Soft-Tissue Sarcomas: Comparison With Tumor Morphology, Circulating and Tumor Biomarkers, and Gene Expression. American Journal of Roentgenology. 204(1). W11–W18. 26 indexed citations
14.
Lee, Hae‐June, Tae‐Min Kim, T.S. Karin Eisinger‐Mathason, et al.. (2012). Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia‐inducible factor 1α. International Journal of Cancer. 132(1). 29–41. 34 indexed citations
15.
Riedel, Till, et al.. (2012). Augmented service in the factory of the future. 1–2. 8 indexed citations
16.
Dayyeh, Barham K. Abu, May Yang, Bryan C. Fuchs, et al.. (2011). A Functional Polymorphism in the Epidermal Growth Factor Gene Is Associated With Risk for Hepatocellular Carcinoma. Gastroenterology. 141(1). 141–149. 108 indexed citations
17.
Yoon, Sam S., Dan G. Duda, Daniel Karl, et al.. (2010). Phase II Study of Neoadjuvant Bevacizumab and Radiotherapy for Resectable Soft Tissue Sarcomas. International Journal of Radiation Oncology*Biology*Physics. 81(4). 1081–1090. 66 indexed citations
18.
Lin, Kevin, Alexander F. Bagley, Alexia Y. Zhang, et al.. (2010). GOLD NANOROD PHOTOTHERMAL THERAPY IN A GENETICALLY ENGINEERED MOUSE MODEL OF SOFT TISSUE SARCOMA. Nano LIFE. 1(03n04). 277–287. 21 indexed citations
19.
Yoon, Sung‐Soo, Daniel Karl, Edwin Choy, et al.. (2010). A phase II study of neoadjuvant bevacizumab and radiation therapy for resectable soft tissue sarcomas.. Journal of Clinical Oncology. 28(15_suppl). 10023–10023. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Manoj Kandpal Breakdown of academic impact, for papers by Sheng Han Breakdown of academic impact, for papers by Thu Le Trinh Breakdown of academic impact, for papers by Ningning Dong Breakdown of academic impact, for papers by Takao Ide Breakdown of academic impact, for papers by Alessio Fabozzi Breakdown of academic impact, for papers by Dilara Akhoundova Breakdown of academic impact, for papers by Ágnes Holczbauer
Rankless by CCL
2026